Guidance
Update information
June 2018: This guideline is an update of the NICE guideline on dementia (CG42, published November 2006) and replaces it. It also replaces recommendation 1.3 in the NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease.
Minor changes since publication
October 2024: We added links to the Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Updates on valproate use in men and their partners and the risks associated with valproate in men and women under 55.
October 2021: We have linked to the NICE guideline on supporting adult carers in recommendation 1.11.4.
October 2018: Links have been added to patient decision aids from some recommendations.
ISBN: 978-1-4731-2978-8